Inovio prepping for failure of cervical cancer vaccine study, TheStreet says With results due "any day" from Inovio Pharmaceuticals' phase II study of its vaccine for cervical pre-cancerous lesions, the company's CEO is "walking back expectations" and "laying the foundation for a massive spin job," according to TheStreet's Adam Feuerstein. The author said he suspects Inovio already has data in hand and that recent "red flags" by CEO Joseph Kim and the company may be intended to "cushion the vaccine's failure." Reference Link
News For INO From The Last 14 Days
Check below for free stories on INO the last two weeks.